-
Featured
Mindfulness-based Cognitive Therapy Shows Promise for Treating Depression in Chronically Ill Patients
Mass General researchers were part of the first group to investigate whether mindfulness-based cognitive therapy might relieve depression in people with chronic pain.
-
Featured
Women with Major Depression During Pregnancy Have High Rates of Recurrence During Their Child's Formative Years
Depression during pregnancy is highly likely to recur after delivery, Mass General researchers have determined. The finding implies that maternal depression is a major confounder when assessing the influence of prenatal antidepressant exposure on child neurodevelopment.
-
Featured
Effective Ketamine Dosages for Treatment-resistant Depression Identified
Ketamine has long been used as a general anesthetic, but more recent research has found it to be effective in rapidly relieving depression symptoms when given at low, subanesthetic doses. New research identifies two optimal dosages.
-
AI Approach Can Predict Placebo Responders in Clinical Trials in Major Depressive Disorder
Maurizio Fava, MD, and colleagues created an artificial intelligence–assisted method for predicting each individual's propensity to respond to placebo in randomized, controlled trials of interventions for major depressive disorder, which can make treatment arms more comparable and boost the efficacy signal.
-
Primary Insomnia and Major Depressive Disorder May Share Underlying Neurobiology
Kathleen L. Benson, PhD, John W. Winkelman, MD, PhD, and Atilla Gönenç, PhD, detected similar impairments in four white matter tracts on brain diffusion tensor imaging in individuals with major depressive disorder or primary insomnia compared with healthy controls, suggesting shared neurobiology of the two disorders.
-
Youth Team Sports Participation Associates With Reduced Psychopathology Via Interaction With Biological Risk Factors
Keiko Kunitoki, MD, Joshua L. Roffman, MD, MMSc, and colleagues have linked participation in team sports more strongly to childhood mental health, compared with previous reports, by identifying polygenic risk and subcortical volume as potential intermediate biological mechanisms.
Depression Contributors
-
Cristina Cusin, MD
Assistant Professor in Psychiatry, Staff Psychiatrist, Depression Clinical and Research Program
Recent Article
Q&A with Dr. Cristina Cusin: What to Know About Esketamine and Ketamine Treatment
-
David Mischoulon, MD, PhD
Director, Depression Clinical and Research Program
Recent Article
Mindfulness-based Cognitive Therapy Shows Promise for Treating Depression in Chronically Ill Patients
-
Maurizio Fava, MD
Psychiatrist-In-Chief; Director, Division of Clinical Research of the MGH Research Institute, Executive Director, Clinical Trials Network and Institute (CTNI), Massachusetts General Hospital, Associate Dean for Clinical & Translational Research, Slater Family Professor of Psychiatry, Harvard Medical School
Recent Article
AI Approach Can Predict Placebo Responders in Clinical Trials in Major Depressive Disorder
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.